Intraductal carcinoma in situ of the breast is a disease with a good prognosis, with a five-year survival rate of more than 95%, and a ten-year survival rate of 90% for some patients. Intraductal carcinoma in situ means that the cancer cells have not yet infiltrated under the basement membrane and the risk of metastasis is small. It should be detected and treated early. Currently, the treatment for intraductal carcinoma in situ is mainly surgery, with conventional endocrine therapy after surgery. Generally speaking, the five-year survival rate (which reflects the severity of the cancer) of patients can reach 95%, and the ten-year survival rate of some patients without high-risk factors can even be above 90%. Intraductal carcinoma in situ of the breast is a disease with a fairly good prognosis, and patients should actively cooperate with the doctor’s treatment plan.